# Rheos Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rheos-medicines

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.rheosrx.com
- Total disclosed funding: $60M
- Latest round: Series A (Mar 22, 2018)
- Investors on record: 1

## About

Rheos Medicines, Inc. specializes in innovative drug delivery systems aimed at enhancing therapeutic efficacy and patient outcomes. The company focuses on addressing specific medical conditions through optimized medication delivery.Rheos Medicines, Inc. develops advanced drug delivery systems and was founded in 2017 in Cambridge, US. The company has engaged in 2 investment deals, with the most recent funding round in October 2018, raising USD 21.00 mn. The CEO is Barbara Fox, who has a background in founding and leading biotech firms in the past.RheosRx specializes in developing innovative solutions aimed at enhancing patient outcomes through their flagship product, a proprietary drug delivery system designed to optimize the therapeutic effect of medications. This technology focuses on addressing specific medical conditions by improving the bioavailability and targeted delivery of active pharmaceutical ingredients. The company’s offerings are tailored primarily to healthcare providers, including hospitals and clinics, as well as directly to patients who require specialized treatment options. The products have been strategically launched in key geographical markets such as North America and Europe, where there is a significant demand for advanced medical therapies. By leveraging science and technology, RheosRx aims to meet the evolving needs of healthcare practitioners and patients alike, providing effective solutions that enhance treatment efficacy.RheosRx's revenue model is primarily structured around direct sales and partnerships with healthcare institutions that utilize their drug delivery systems. The company engages in B2B transactions, offering its products to hospitals and clinics seeking innovative solutions for patient care. These transactions are structured as contractual agreements, where healthcare providers order products based on their specific needs. RheosRx offers a tiered pricing plan that accommodates different scales of purchase, allowing for flexibility based on order volume. Their flagship product, recognized for its unique delivery mechanism, forms the cornerstone of their revenue generation efforts, enabling the company to establish a robust client base in the healthcare sector.Rheos Medicines, Inc. plans to utilize the recent funding of USD 21.00 mn, raised in October 2018, to enhance their product offerings and expand into new markets. The company is currently designing new drug delivery products aimed at improving patient outcomes, with launches expected in the coming years. RheosRx is targeting expansion into additional markets in Europe and Asia by 2025 to meet rising demand for advanced therapeutic solutions.

## Funding rounds

- Series A, Mar 22, 2018, $60M — Third Rock Ventures

## Investors

- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A